India-Africa Summit focus on generics and Indian investment in Africa

30 October 2015
india-africabig

Availability of affordable generic medicines from India has been a game changer in the way millions of lives have been saved over the decades, and is of particular interest in the ongoing third India-Africa Summit, the most ambitious diplomatic outreach event in over two decades, reports The Pharma Letter’s India correspondent.

Though India's trade with Africa has doubled to about $72 billion since 2007, it is nowhere near China's $200 billion which makes the latter the continent's largest trading partner.

Despite this, Gambia's Health Minister Omar Sey pointed out the need to ensure a framework on healthcare between the two nations, stating that the framework for affordable healthcare in Africa "requires breadth, scope and depth." Mr Sey called upon ‘India Inc’ to provide essential and life saving’s drugs to his countrymen, and also urged for investments to enable it to provide suitable and affordable healthcare facilities to the people of Gambia.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More on this story...





Today's issue

Company Spotlight





More Features in Generics